About
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Visit company website
5 years, 6 months ago
CanSino Biologics Inc is currently in a long term uptrend where the price is trading 23.7% above its 200 day moving average.
From a valuation standpoint, the stock is 117.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2855.7.
CanSino Biologics Inc's total revenue rose by 364.9% to $2M since the same quarter in the previous year.
Its net income has dropped by 16.4% to $-74M since the same quarter in the previous year.
Finally, its free cash flow fell by 277.7% to $-306M since the same quarter in the previous year.
Based on the above factors, CanSino Biologics Inc gets an overall score of 2/5.